Why is traditional broad-spectrum treatment becoming obsolete?

Historically, Parkinson’s was treated as a monolithic condition. Modern genomic research has revealed it is a collection of subtypes with varying biological drivers. For biopharma companies, this means the end of the "one size fits all" blockbuster model in neurology.

Companies are now segmenting the market based on genetic markers such as GBA (Glucocerebrosidase) and LRRK2 (Leucine-rich repeat kinase 2). These subpopulations, while smaller, provide a more direct path to efficacy in clinical trials.

How do Targeted Parkinson’s Therapies influence clinical R&D?

The development of Targeted Parkinson’s Therapies is reshaping the commercial landscape by allowing for premium pricing based on genetic specificity. In 2024, companion diagnostics are becoming a mandatory part of the development cycle. For strategy heads, this requires a dual focus on therapeutic development and widespread genetic testing infrastructure.

What is the 2025 outlook for GBA-targeted agents?

By 2025, GBA-targeted small molecules and gene therapies are expected to dominate the innovation headlines. Because GBA-mutated Parkinson’s often progresses more rapidly, these therapies have a clear value proposition for reducing the total cost of care for healthcare systems, potentially accelerating their adoption.

• Shift toward "biomarker-positive" inclusion criteria in trials.
• Rising demand for commercial-scale genetic sequencing in neurology.
• Increase in orphan drug designations for specific Parkinson’s genetic variants.

2025 Regulatory Strategy

In 2025, regulatory bodies are likely to encourage the use of surrogate biomarkers to grant accelerated approvals. This will drastically shorten the time-to-market for innovative therapeutics, provided that manufacturers can demonstrate a clear link between the biomarker and clinical improvement.

Author: Sofiya Sanjay

Designation: Healthcare Research Consultant, Market Research Future

About: At Market Research Future (MRFR), we enable organizations to unravel complex industries through Cooked Research Reports (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services. Our studies across products, technologies, applications, end users, and global to country-level segments help decision-makers see more, know more, and do more.

Contact: 99 Hudson Street, 5th Floor, New York, NY 10013, USA | (855) 661-4441 (US) | +44 1720 412 167 (UK) | +91 2269738890 (APAC) | info@marketresearchfuture.com